UK CDMO SCM Pharma Limited Appoints BD Director

UK CDMO SCM Pharma Limited Appoints BD Director


October 2013 -- CONTRACT development and manufacturing organisation (CDMO) SCM Pharma has strengthened its commercial management team after the appointment of an experienced new director.

Simon Bellamy joins the sterile manufacturing specialist as Business Development Director and will be primarily responsible for bringing in new clinical trials business as well as looking for small commercial opportunities for the company's new £6m ($10m) facility in Newburn.

He brings 30 years' experience in the pharmaceutical industry with his most recent business development roles at Catalent Pharma Solutions and Piramal Healthcare.

Dianne Sharp, managing director at SCM Pharma, said: "Attracting Simon to our business is a major coup given his past experience in the contract manufacturing arena and he will no doubt add a huge amount of value to our exciting growth plans.

"We now have two of the finest sterile filling facilities in Europe catering for development, clinical trial projects and commercial supply, which gives Simon and his team a compelling service offering to take to the market.

"The flexible nature of our approach to new projects combined with our expanded capacity and capability will effectively allow us to offer clients a blank canvas at this year's ICSE/CPhI, which will no doubt be of interest to companies with more complex manufacturing processes, products or small batch requirements," added Dianne.

Having graduated with a First Class honours degree in Chemistry from Sheffield University, Simon is the latest high-profile director to join the award-winning SCM Pharma. He said: "The sterile market is one of the highest growth area in pharmaceutical outsourcing at the moment so offers incredible opportunity for growth for SCM Pharma, which was a major factor in joining this exciting business.

"Having worked for the big CMOs, it is exciting to be working within a more specialised company at a relatively early stage of its growth. SCM Pharma has an incredible culture, which is markedly different from others within this market.

"I am very much looking forward to the challenge of growing the business and learning more about the parenteral dosage forms applications we can offer, most of which have a direct impact on patients in critical care areas such as oncology," added Simon.

SCM Pharma specialises in the sterile production of products for clinical trials along with the supply of licensed drugs in niche markets. Its new facility was given the go ahead for production following a successful inspection from the MHRA this summer, which reinforces its expertise in vial, ampoule and syringe filling, particularly when dealing with potent products requiring high containment.

In a bold move, the CDMO will use ICSE at CPhI in Frankfurt as a platform to offer pharmaceutical companies across the world the opportunity to design their clinical and contract manufacturing projects from a 'blank canvas' of cleanroom space.

In contrast to contract manufacturers, SCM Pharma is inviting drug developers and licensed product owners the opportunity to utilise dedicated space at its newsite to design a process around their specific product manufacturing needs. | [email protected]